Gene · 4100
NIH grants735
NIH grants whose papers are about the gene, through NIH's grant-paper links.
161 to 180 of 735
Download this page as JSON| Grant | Title | MAGEA1 papers | Newest fiscal year |
|---|---|---|---|
| P50CA070907 | Targeting Lung Cancer Vulnerabilities | 3 | 2024 |
| P30ES000002 | Harvard Chan School NIEHS Center for Environmental Health | 2 | 2024 |
| R01CA247471 | Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer | 2 | 2024 |
| T32CA009135 | Training in Cancer Biology Training Grant | 2 | 2024 |
| T32GM007863 | Michigan Medical Scientist Training Program | 2 | 2024 |
| ZIABC011714 | Translational Immunology | 2 | 2024 |
| K02AG068617 | Aging, immunosenescence and glioblastoma | 1 | 2024 |
| K08CA241523 | Therapeutic applications of CD4+ T cells specific for oncogenic driver mutations | 1 | 2024 |
| P01AG066597 | From cells to complex syndromes: using networks to understand heterogeneity in TDP-related frontotemporal degeneration and aging | 1 | 2024 |
| P01CA196539 | Role of Histone and Histone-like Mutations in the Oncogenesis of Human Cancers | 1 | 2024 |
| R01CA204120 | Novel Methods for Identifying Genetic Interactions for Cancer Prognosis | 1 | 2024 |
| R01CA235159 | TCR engineering of human T cells for immunotherapy of hepatocellular carcinoma | 1 | 2024 |
| R01CA245318 | Antigen-independent prediction and biomarker identification of cancer-specific T cells | 1 | 2024 |
| R01CA251599 | Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer | 1 | 2024 |
| R01GM147310 | The Regulation and Function of the Ubiquitin-Sensing Kinase TNK1 | 1 | 2024 |
| R01NS110703 | MAPK as target of glioma immunoediting by CD8 T-cells, and predictor of response to immunotherapy | 1 | 2024 |
| R37CA230636 | Tumor-intrinsic signaling pathways restrict anti-tumor immunity in hepatocellular carcinoma | 1 | 2024 |
| T32CA060397 | Postdoctoral Training in Head and Neck Oncology | 1 | 2024 |
| T32CA108462 | Molecular and Cellular Mechanisms in Cancer | 1 | 2024 |
| U01DK124165 | Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients | 1 | 2024 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4100/grants?page=9